Neumora Therapeutics 8-K Report: Key Insights from January 2025 Filing

Here are the key insights extracted from the provided financial report section:

1. Entity Information:

• Company Name: Neumora Therapeutics, Inc.
• CIK Number: 0001885522
• Stock Ticker: NMRA
• Exchange: NASDAQ

2. Filing Information:

• Form Type: 8-K (Current Report)
• Filing Date: January 13, 2025

3. Company Details:

• Incorporation State: Delaware (DE)
• EIN: 84-4367680
• Address: 490 Arsenal Way, Suite 200, Watertown, MA 02472
• Contact Number: (857) 760-0900

4. Securities Information:

• Security Type: Common Stock
• Par Value: $0.0001 per share

5. Reporting Period:

• Period Start Date: January 13, 2025
• Period End Date: January 13, 2025

6. XML Context:

• The document is structured in XBRL format, indicating it is likely intended for electronic filing and reporting purposes.

7. No Additional Flags:

• There are no indications of errors or additional flags in the report section, as all false statements imply no relevant issues.

This summary encapsulates the essential details regarding Neumora Therapeutics, its current report filing, and relevant corporate information that investors and analysts would find pertinent.